NCT06144944 2026-01-30
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT04126525 2025-09-11
NeoATP
RenJi Hospital
Phase 2 Active not recruiting
NCT05165225 2024-11-29
Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT04398914 2022-03-31
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting